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A b s t r a c t  
 
Liquisolid Compacts technique has potential to develop sustained release formulations. It involves 
conversion of liquid drug (either solution or suspension) in non-volatile solvent into free-flowing, non 
adherent, dry looking and readily compressible powder. In the present work, an attempt was made to 
develop such formulation of Diltiazem HCl and evaluation using Response surface methodology. 
Liquisolid compacts were prepared by dissolving Diltiazem HCl in Polyethylene Glycol 400. Then a 
binary mixture of carrier-coating material, Avicel and Aerosil, was added to liquid medication under 
continuous mixing in mortar. The HPMC K4M was used as adjuvant for sustaining the drug release.  
The pre-compression studies for all the formulations were also carried out. The Liquisolid compacts 
were evaluated in-vitro dissolution studies. Statistical Evaluation: The experimental data was 
evaluated using Design Expert Software. The % Drug Concentration, ratio of Carrier to Coating 
material and amount of HPMC K4M are taken as three factors. Response Surface methodology was 
used to study the influence of the each factor on the response. The present investigation showed 
that Polyethylene Glycol 400 has important role in release retardation of drug in Liquisolid compacts. 
The reduction in Tg can be reason for same. The Response surface methodology showed that all 
the factors were significantly affect the release at 16 hrs. 
Keywords: Liquisolid compacts, Carrier, Coating material, HPMC K4M, Response surface 
methodology 
 
 
Introduction 
Sustained release dosage form maintains therapeutic blood or 
tissue levels of the drug for extended period of time with 
minimized local or systemic adverse effects.  Further, they are 
economic and show greater patient compliance. Various 
approaches have been used by researchers to sustain drug 
release in the form of tablets, among which control of drug 
dissolution rate is one of the best and most successful approach 
due to its simplicity and low cost.[1]  
Liquisolid system is novel technique developed by Spireas et 
al.[2] It involves conversion of liquid drug (either solution or 
suspension) in non-volatile solvent into free-flowing, non 
adherent, dry looking and readily compressible powder. This is 
done by blending it with calculated amount of carrier and coating 
materials. The drug is adsorbed and absorbed on carrier material 
while coating materials is essential to provide flowable powder 
mixtures. Previously this method has been used for enhancing the 
dissolution rate of poorly water soluble drugs. [3-9] If the 
hydrophobic carrier is used instead of the hydrophilic carrier, it 
can be used as sustained release system.[10, 11] Because of its 
low cost, simple formulation technique and capability of industrial 
production serve to be advantages of this technique. [12]  
Diltiazem hydrochloride (DHL) is calcium channel blocker and is 
an effective agent in hypertension and angina (variant & classical 
angina). Its use extent in the management of angina pectoris, 
arrhythmia and hypertension.The half-life of the drug is about 4.5 
hours and the usual oral dosage regimen is 60 to 360 mg. The 
drug is freely water soluble and hence judicious selection of 
release retarding excipients is necessary to achieve a constant in 
vivo input rate of the drug. As a result of its short half-life and to 
reduce frequent administration of dosage form and to improve 
patient compliance, a sustained-release formulation DHL is 
desirable.[13]  
The objective of present study is to evaluate the Liquisolid 
compacts by using Response Surface Methodology (RSM). Also, 
attempt was made to study the influence of formulation factor on 
drug release as formulation characteristics. In this study, The 
Design Expert® Software (DXT 8.0.4.1version, Stat-ease Inc) is 
used to analyze the experimental data. The experimental data 
was fitted into the Historical data option of RSM. This is used to 
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evaluate the data that is already generated. The software gives a 
mathematical model which is highly significant and used to 
navigate within design space. The model is also useful to predict 
the response at various levels of the formulation factors.   
Materials and methods  
Materials 
DHL is obtained as a gift sample from the ACE Pharma, Mumbai. 
Avicel pH 102 was kindly gifted by Reliance Cellulose Products 
Ltd. HPMC K4M was obtained as a gift sample from Colorcon 
Asia Pvt. Ltd. Aerosil 200 and Polyethylene Glycol 400 (PEG 400) 
and other ingredients are of analytical grade. 
Solubility Studies 
Solubility Studies of DHL was carried out in PEG 400. For this 
saturated solution of DHL was prepared by adding excess of DHL 
to the PEG 400 and shaking on the shaker (Joshi Scientific Cop. 
India) for 48 Hrs at 370C. The Solutions were filtered through a 
0.45 micron filter. One ml of the above solution was diluted with 
water up to 100ml. One ml of this solution was removed and 
further diluted to 100ml with distilled water. This solution was 
analyzed by UV-spectrophotometer at a wavelength of 237 nm 
(Systronics 2201 UV-Vis Spectrophotometer).  
Application of Mathematical model 
To calculate the amount of carrier and coating material and to 
maintain acceptable flowability and compressibility, the 
mathematical model described by Spireas et al was used. In this 
study, Polyethylene Glycol 400 was used as liquid vehicle; Avicel 
PH 102 and Aerosil 200 were used as the carrier and coating 
materials, respectively. Concentration of the drug in Polyethylene 
Glycol 400 was taken as 50 % and 60 % w/w. The carrier to 
coating material ratios were taken as 2 and 3.  
Flowable liquid retention potential (Φ value) of powder excipients 
was used to calculate the required ingredient quantities. 
Therefore, carrier to coating ratios (R) and liquid load factors (Lf) 
of the formulations are related as follows:  
                      Lf= Φ + Φ (1/R)                                                  (1) 
 
Where, Đ Φ and ĐΦ are the Đ values of carrier and coating 
materials, respectively and they are constant. Liquid load factor 
(Lf) is defined as the ratio of the weight of liquid medication (W) 
over the weight of the carrier powder (Q) in the system, which 
should be possessed by an acceptably flowing and compressible 
Liquisolid system.[14, 15] That is,  
                     Lf=W/Q                                                                   (2) 
 
Where, W is amount of drug in liquid vehicle 
The ratio R of powder is defined as,  
                     R=Q/q                                                                     (3) 
Where, R is the ratio between the weights of carrier (Q) and 
coating (q) materials present in the formulation.  
 Hence to calculate the required weights of carrier (Q) and coating 
(q) a material first from equation 1, Lf was calculated at the 
different levels of R. By using equation 2 amount of Q was 
determined and q was determined by using equation 3. Liquisolid 
compacts were formulated as shown in Table 1.  
 
Preparation of Liquisolid Compacts 
For the preparation of Liquisolid compacts of solid drug, non-
volatile solvent PEG 400 was employed to prepare the drug 
solution or suspension having different drug concentrations (50 % 
w/w and 60 % w/w). The desired quantities of solid drug and PEG 
400 were accurately weighed in a 20 ml glass beaker and then 
heated to with constant stirring, until a homogeneous drug 
solution was obtained. Selected amounts (W) of the resulting hot 
liquid medications were incorporated into calculated quantities of 
carrier and coating materials. During the first stage, the system 
was blended at an approximate mixing rate of one rotation per 
second for approximately one minute in order to evenly distribute 
the liquid medication into the powder. In the second mixing stage, 
the liquid/powder admixture was evenly spread as a uniform layer 
on the surfaces of the mortar and left standing for approximately 
five minutes to allow the drug solution or liquid drug to be 
absorbed in the interior of the powder particles. In the third stage, 
the powder was scraped off the mortar surfaces by means of an 
aluminium spatula. Then, HPMC K4M was added to this mixture 
and blended with mortar. This gives final formulation which was 
compressed into tablets using single punch tablet compression 
machine.  
Differential Scanning Calorimetry (DSC) 
Thermogram of the sample of Liquisolid was recorded using 
Differential scanning calorimeter (STARe SW 10.00). Samples 
were placed in Aluminium pans and the lids were crimped. 
Thermal behaviour of the sample was investigated under Nitrogen 
gas at scanning rate of 200C/min over the range of 40-3000C. 
 
In vitro drug release studies 
The developed Liquisolid compacts (n=3) were subjected to 
release studies using USP type I dissolution apparatus at 100 rpm 
with a constant temperature water bath at  37ĈC μ 0.5 ĈC. 
Dissolution medium used was pH 1.2 (900 ml) for first 2 hours and 
pH 6.8 (900 ml) for next for remaining hours. The samples were 
withdrawn (10 ml) at different time interval and replaced with an 
equivalent amount of fresh medium. After filtration through 
Whatman filter paper 0.45 micron concentration of Diltiazem 
Hydrochloride was determined spectrophotometrically at 237 nm 
(Systronics 2201 UV-Vis Spectrophotometer, India). 
Statistical analysis of the data and its validation 
The Design Expert® Software (DXT 8.0.4.1version, Stat-ease Inc) 
was used to analyze the experimental data and obtain the 
polynomial model. The experimental data was fitted into the 
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Historical data option of the RSM. This was used to evaluate the 
data that was already generated.  
Here, the Drug Concentration (% w/w) in liquid vehicle X1, the 
ratio of the carrier to coating material (X2) and amount of HPMC 
K4M (X3) were independent variables, whereas % drug release at  
the 2 hrs (Y1) and % drug release at the 16 hr (Y2) were 
dependent variables. The factors their actual values were shown 
in the Table 2. Polynomial models for factors were generated for 
two the response variables (Y1 
and Y2) by means of multiple 
linear regression analysis. In order to validate the polynomial 
equations, one optimum checkpoint and two random check points 
were selected by intensive grid search, performed over the entire 
experimental domain. Values of two responses were predicted for 
the each factor and two additional random check points covering 
the entire range of experimental domain. These predicted values 
were compared with the resultant experimental values and 
percentage prediction error was calculated. 
Results and Discussion  
Application of Mathematical model for design of 
Liquisolid systems 
 According to Liquisolid hypothesis of Spireas et al., drug 
candidate dissolved in liquid nonvolatile vehicle and incorporated 
into carrier material having porous structure and closely matted 
fibers in its interior, phenomenon of both adsorption and 
absorption occurs.  Thus, the drug in the form of liquid medication 
is first get absorbed in the interior of particles of carrier and after 
saturation of this process it gets adsorbed into internal and 
external surfaces of carrier. The Liquisolid systems get desirable 
flow properties due to the Coating materials such as, Aerosil 200, 
which have high adsorptivity and greater surface area. 
Mathematical model equation for Avicel PH 102 and Aerosil 200 
in PEG 400 can be given according to values of Phi (Đ) as given 
by Spireas et.al.[16] 
 
Lf = 0.005 +3.26 (1 / R) 7 
Based on this equation, Lf is calculated by using different R 
values. 
Solubility of DHL in PEG 400 
Determination of solubility is most important aspect in formulation 
of Liquisolid systems. The solubility of Diltiazem Hydrochloride in 
PEG 400 was found to be 60.024mg/ml. 
Differential Scanning Calorimetry (DSC) 
The DSC study showed (Figure 1) that the glass transition temp 
(Tg) of the carrier material found to be decrease (62.46 0C) 
towards the lower side in the Liquisolid formulation than the 
physical mixture (70 0C).  
 
In vitro dissolution studies  
 The results of in vitro drug release from Liquisolid compacts were 
shown in the Figure 2. In Liquisolid, the drug is absorbed and 
adsorbed on the surface of the carrier material. After exposure to 
dissolution medium the drug which is present on the surface of 
the carrier material dissolves in the dissolution medium. This 
might be the reason of the initial burst release from the 
formulation. Formulation with higher amount of the Avicel (F3 and 
F4) showed decrease in the initial burst release than other, since 
more amount of drug was absorbed than adsorbed at the surface 
of the carrier material. 
The mechanism of release prolongation of drug from the 
Liquisolid compacts was likely because of the efficient 
encapsulation of the drug particles by hydrophobic material. The 
major difference between the Liquisolid compacts and other 
dosage forms is the presence of the Liquid vehicle, which act as 
plasticizer. This liquid vehicle reduces the glass transition temp of 
the polymer material by changing intermolecular bonding between 
polymer chains and imparting flexibility. At the temperature above 
Tg, a better coalescence of the polymer material which gives a 
fine network and a matrix with lower porosity and high tortousity. 
This leads to the restricted leaching of the drug from the Liquisolid 
compacts. As the concentration of the drug in the Liquid vehicle 
increases the decrease in the drug release is seen because less 
amount of drug is available in molecular state. But effect of this is 
less prominent than the effect of the hydrophobic carrier material. 
Thus, F3 and F4 batches showed more retarding drug release 
than others, while F5 and F6 showed maximum amount of drug 
release at the end of 16 hrs. Further, the concentration of the 
HPMC K4M also contributes to the release retardation of the drug 
from the compacts. Thus, F6 showed more retarding effect than 
F5. 
Analysis of Data using Response Surface 
Methodology 
Design Expert® Software (DXT 8.0.4.1version, Stat-ease Inc) was 
used to analyze the data. The statistical evaluation of data gave a 
polynomial regression equation that fitted to data was as follows 
   
Y = b0 + b1X1 + b2X2 +b3 X3
                                                    8 
 
Where, b0 was the intercept representing the arithmetic mean of 
all the quantitative outcomes of eight experimental runs; b1 to b3 
were the estimated coefficients from the observed experimental 
values of Y; X1, X2 and X3 were the values of each factors drug 
concentration (% w/w), ratio of carrier to coating material and 
amount of HPMC. The equation represents the quantitative effect 
of factors (X1, X2 and X3) upon the each of the responses; Y1 and 
Y2. Coefficients with one factor represent the effect of that 
particular factor. A positive sign in front of the terms indicates  
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Table 1. Formulation design of Liquisolid Compacts 
Formulation 
Batch 
Drug solution % 
w/w 
Ratio 
R = 
Q/q 
Wt. of drug solution
in gm 
Lf * Avicel
PH 102 (Q) in gm 
Aerosil 
200 
 (q) in gm 
HPMC
K4M in gm 
F1 50 2 0.240 1.635 0.147 0.073 0.050
F2 50 2 0.240 1.635 0.147 0.073 0.075
F3 50 3 0.240 1.091 0.220 0.073 0.050
F4 50 3 0.240 1.091 0.220 0.073 0.075
F5 60 2 0.200 1.635 0.122 0.061 0.050
F6 60 2 0.200 1.635 0.122 0.061 0.075
F7 60 3 0.200 1.091 0.183 0.061 0.050
F8 60 3 0.200 1.091 0.183 0.061 0.075
* Liquid load factor 
 
Table 2 Factors with their actual values 
Sr.No. Factors Level of  factor in actual values 
1 Drug concentration in liquid vehicle (% w/w) 50 60 
2 Ratio of Carrier to Coating material 2 3 
3 Amount of HPMC K4M 50 75 
 
Table 3 AVOVA Results of release at 16 hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 The experimental and predicted values of responses R1 and R2 for optimum formulation and two check points 
Responses A,B,C Optimum
formulation 
60,2,50 
Check point 1 
 
Check point 2
R1 release at 2  
hrs 
Experimental value 31.55 14.13 29.79 
Predicted value 31.82 14.36 29.93 
% PE * -0.86 -1.63 -0.47 
R2 release at 16 hrs Experimental value 92.19 66.24 89.34 
Predicted value 91.58 65.87 88.89 
% PE * 0.66 0.56 0.50 
* %PE= (Experimental value- Predicted value) / Experimental Value * 100 
 
 
Source Sum of Squares df Mean Squares F value p-value 
probe > F 
Model 552.65 3 184.22 23.60 0.0053 
A-A 64.47 1 64.47 8.26 0.0453 
B-B 379.91 1 379.91 48.67 0.0022 
C-C 108.27 1 108.27 13.87 0.0204 
Residual 31.22 4 7.81
Core Total 583.87 7
"Pred R-Squared" 0.7861
"Adj R-Squared"  0.9064
Adeq Precision 13.575
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Figure 1. Tg study of a) Physical Mixture b) Liquisolid Formulations. 
 
 
Figure 2. In vitro drug release of Liquisolid compact (a) of Formulation F1 to F4 (b) of Formulation F5 to F8. 
  
 
Figure 3. Influence of (a) % Drug concentration (b) Ratio of Carrier to coating material (c) HPMC concentration on % drug release at 16 hrs. 
Kulkarni et al. International Journal of Drug Delivery 4 (4) 427-433 [2012] 
 
PAGE | 432 |
 
 
synergistic effect while negative sign indicates antagonistic effect 
of the factors. The significance of the model was estimated by 
applying analysis of variance (ANOVA), at 5% significance level. 
A model is considered significant if the p-value is less than 0.05.  
Influence of Formulation Factor on % Drug release at 
16 Hrs 
Out of all the Liquisolid formulations, the drug release at the end 
of the 16 hrs should be maximum. Hence, in the evaluation of 
Liquisolid compacts, release at the end of 16 hrs is also important 
parameter. 
The influence of formulation factors of Liquisolid compacts on 
release at 16 hrs was given by equation 10. This was the linear 
polynomial equation generated as significant mathematical model 
by the software. The significant level of the model was explained 
with the help of ANOVA results shown in Table 3. 
Release at end of 16 Hrs (R2) = +99.79750 +0.56775X1 -
13.78250X2 -0.29430X3           9 
From the Table 3 Value of "Prob > F" for model, is less than 0.05 
and The Model F value of 23.60 implies that the model is 
significant. The Values of "Prob > F" for X1, X2 and X3 are also 
less than 0.05 or between 0.05-0.10, that is they are significant 
model terms. Thus, they will contribute in generating the response 
Y2. 
From the Table 3, the "Pred R-Squared" of 0.7861 is reasonable 
agreement with "Adj R-Squared" of 0.9064, their difference should 
not greater than 0.2, and this may indicate a good fitting of the 
model. Thus, the polynomial equations can also be used to draw 
conclusions considering the magnitude of coefficient and the 
mathematical sign it carries, that is, positive or negative."Adeq 
Precision" measures the signal to noise ratio.  A ratio greater than 
4 is desirable. A ratio of 13.575 indicates an adequate signal.  
This model can be used to navigate the design space. 
The positive coefficient of variable X1, i.e. Drug Concentration (% 
w/w) in case of response i.e. % drug release at 16 hrs indicated 
that as the concentration of drug in liquid vehicle was increased; 
the % drug release was also increased. The relationship between 
the variables was further elucidated by using the response 
surface plot shown in Figure 3. It was observed from the figure 
that as the drug concentration in liquid vehicle increases the drug 
release also increases and vice versa.  
The negative coefficient of variable X2, i.e., ratio of Carrier to 
Coating material in case of response i.e. % drug release at 16 hrs 
indicates that as ratio of Carrier to Coating material was 
increased; % drug release value was decreased. The relationship 
between the variables was further elucidated by using the 
response surface plot shown in Figure 3. It was observed from the 
figure that as the ratio of carrier to coating material increases, 
drug release decreases and vice versa.  
The negative coefficient of variable X3, that is, HPMC in case of 
response, i.e. % drug release at 16 hrs indicated that as the 
concentration of HPMC was increased; the % drug release value 
was decreased. The relationship between the variables was 
further elucidated by using the response surface plot shown in 
Figure 3. It was observed from the figure that as the amount of 
HPMC K4M increases, drug release decreases and vice versa. 
Optimization of the Formulation 
The optimized formulation was obtained with the help of the 
above developed mathematical model by applying the constraints 
to the two responses as follows,  
                  R1 i.e. % drug release at 2 hrs which should be above 
30 % and 
                  R2 i.e. % drug release at 16 hrs which should be 
above 90% 
The experiments were carried out according to the composition 
obtained for optimum formulation. The optimum formulation was 
evaluated for the dissolution profile.  In order to evaluate the 
reliability of the developed mathematical model, two additional 
check points were taken estimated by use of generated model 
covering the entire experimental domain. Table 4 gives the levels 
of each factor, Drug concentration in % w/w (A), ratio of Carrier to 
coating material (B) and amount of HPMC K4M (C) of optimum 
formulation and two random check points with their experimental 
values, predicted values and percentage prediction error. 
Conclusion 
The present study showed that Liquisolid technique can be 
adopted for the optimization of the sustained release formulation 
of the Diltiazem HCL using Polyethylene glycol 400 and HPMC 
K4M. The FT-IR studies show compatibility between Drug and 
excipients. The data analyze by RSM shows that F5 formulation is 
optimized formulation among all the batches.  
Acknowledgement 
Authors are thankful to ACE Pharma, Mumbai, Reliance Cellulose 
Products Ltd. and Colorcon Asia Pvt. Ltd. for providing the 
Diltiazem HCL, Avicel PH 102 and HPMC K4M. 
 
 
References 
 
[1]. Jantzen GM, Robinson JR. 
Sustained and controlled-release 
drug delivery systems. In: Banker 
GS, Rhodes CT, editors. Modern 
Pharmaceutics. 3rd edition. New 
York: Marcel Dekker,1996; pp. 575-
593. 
[2]. S. Spireas U.S. Patent 6 (423), 339 
B1 (2002).  
[3]. Leopold CS, Hentzschel CM, 
Alnaief M, Smirnova I, Sakmann A. 
Kulkarni et al. International Journal of Drug Delivery 4 (4) 427-433 [2012] 
 
PAGE | 433 |
 
Enhancement of griseofulvin 
release from liquisolid compacts. 
Eur. J.  Pharm. Biopharm. 2012; 
80:130ă135. 
[4]. Yadav AV, Shete AS, Dabke AP. 
Formulation and Evaluation of 
Orodispersible Liquisolid Compacts 
of Aceclofenac. Indian J.Pharm. 
Educ. Res. 2010; 44 (3): 227-235. 
[5]. Elkordy AA, Tiong N. Effects of 
liquisolid formulations on dissolution 
of Naproxen. Eur. J.  Pharm. 
Biopharm. 2009; 73: 373ă384. 
[6]. Javadzadeh Y, Siahi-Shadbad MR, 
Barzegar-Jalali M, Nokhodchi A. 
Enhancement of dissolution rate of 
Piroxicam using liquisolid compacts. 
Farmaco. 2005; 60: 361ă365. 
[7]. Spiro Spireas, Srinivas Sadu. 
Enhancement of Prednisolone 
dissolution properties using 
liquisolid compacts. Int. J. 
Pharm.1998; 166: 177ă188. 
[8]. Javadzadeh Y, Jafari-Navimipour B, 
Nokhodchi A. Liquisolid technique 
for dissolution rate enhancement of 
a high dose water-insoluble drug 
(carbamazepine). Int. J. Pharm. 
2007; 341: 26ă34. 
[9]. Gubbi S, Jarag R. Liquisolid 
Technique for Enhancement of 
Dissolution Properties of 
Bromhexine Hydrochloride. 
Research J. Pharm. and Tech. 
2009; 2 (2): 382-386. 
[10]. Nokhodchi A, Javadzadeh Y, 
Musaalrezaei Leila. Liquisolid 
technique as a new approach to 
sustain Propranolol hydrochloride 
release from tablet matrices. Int. J. 
Pharm. 2008; 362:102ă108. 
[11]. Nokhodchi A, Aliakbar R, Desai S, 
Javadzadeh Y. Liquisolid compacts: 
The effect of cosolvent and HPMC 
on theophylline release. Colloids 
and Surfaces B: Biointerfaces. 
2010; 79:262ă269. 
[12]. Gonjari ID, Karmarkar AB, Hosmani 
AH. Evaluation of in vitro dissolution 
profile comparison methods of 
sustained release Tramadol 
Hydrochloride Liquisolid compact 
formulation with marketed sustained 
release tablets. Digest Journal of 
Nanomaterials and Biostructures. 
2009; 4: 651 ă 661. 
[13]. Naga Raju. Potnuri G. Rao D, 
Ramana G, Rao AS. Design and 
evaluation of Diltiazem 
hydrochloride matrix tablets by 
using gum olibanum. Der 
Pharmacia Lettre. 2011;3: 304. 
[14]. S. Spireas U.S. Patent 6 (423), 339 
B1 (2002).  
[15]. Gonjari ID, Karmarkar AB, Hosmani 
AH. Evaluation of in vitro dissolution 
profile comparison methods of 
sustained release Tramadol 
Hydrochloride Liquisolid compact 
formulation with marketed sustained 
release tablets. Digest Journal of 
Nanomaterials and Biostructures. 
2009; 4: 651 ă 661. 
[16]. S. Spireas U.S. Patent 6 (423), 339 
B1 (2002).     
 
 
 
